Showing posts with label asthma. Show all posts
Showing posts with label asthma. Show all posts

Pathology: Asthma




What is it?

· Chronic inflammatory disorder of airways

Clinical

· Recurrent wheezing

· Cough

· Dyspnea

· Chest tightness

Causes?

· Repeated hypersensitivity

· Late-phase reaction

Results?

· Triad

o Intermittent / reversible airway obstruction

o Chronic bronchial inflammation

o Bronchial smooth muscle cell hypertrophy and hyperactivity

Epidemiology?

· 70% - extrinsic / atopic – due to IgE and Th2-mediated immune response to environmental antigens

· 30% - intrinsic/non-atopic – triggered by non-immune stimuli (eg. Aspirin, pulmonary infections

Pathogenesis?

· Genetic predisposition to type 1 hypersensitivity (atopy) and Bronchial hyper-responsiveness to variety of stimuli

· Role of Th2 helper – excessive response against environmental stimuli

o Cytokines – IL4 (IgE production), IL-5 (activation of eosinophils), IL-13(mucus production)

· Role of epithelial cells

o Produces chemokines -> attracts more Th2 and eosinophils + leukocytes à amplying inflammatory reaction.

· Structural changes in bronchial wall (airways remodeling) (ie bronchial smooth muscle hypertrophy)

o Thickening of basement membrane of bronchial epithelium

o Edema and inflammatory infiltrate in bronchial wall

o Increased size of mucosal glands

o Hypertrophy of bronchial muscle wall

· Mast cells – produce growth factors à stimulates SM proliferation

Types?

1) Atopic

· Most common

· Childhood onset

· Family hx – common

· Other atopic diseases (i.e rhinitis, eczema)

· Triggered by environmental antigens

· Skin test -> immediate wheal-flare reaction

· Process? Initial sensitization to inhaled antigens à thus stimulate Th2 cells à cytokines

· IgE production

· IgE binds to mucosal mast cells

· Results : immediate response + late phase reaction

· Subsequent exposure of IgE-coated mast cell to same antigen

· Crosslink and releasing of chemical mediators

· Results : opening of mucosal intercellular junctions à thus allowing penetration of antigen to more mucosal mast cells

· In additions : direct stimulation of subepithelial vagal (parasympathetic) receptors à provokes reflex bronchoconstriction

· Occurs within minutes after stimulation

· Called acute/immediate response (minutes)

o Bronchoconstriction

o Oedema (increased vascular permeability)

o Mucus secretion

· Late phase reaction (hours)

o Mast cells – cytokine release

o Thus, influx of other leukocytes + eosinophils

o Activation of eosinophils -> rich source of leukotrines C4

2) Nonatopic

· Family hx is uncommon

· Serum IgE normal

· No associated allergen

3) Drug-induced asthma

· Eg. Aspirin

· Presentation : recurrent rhinitis + nasal polyps, urticaria, bronchospasm

Status asthmaticus (prolonged severe asthma attack)

Asthma

Asthma

Definition
• Characterized by : recurrent dyspnea, cough, wheeze
• Caused by : reversible airway narrowing
• Factors :
o Bronchial muscle contraction (triggered by stimuli)
o Mucosal swelling/inflammation (mast cells)
o Excess mucus production (inflammatory mediators)

Pathogenesis:?

Microbiology??

Symptoms
• Intermittent dyspnea
• Cough
• Wheeze
• Sputum

Signs
• Tachypnoea
• Audible wheeze
• Hyperventilation
• Diminished air entry
• Polyphonic wheeze
• RR >25/min
• Cyanosis
• Pulse >110bpm

Hx
• Precipitants
• Diurnal variation
• Exercise
• Disturbed sleep
• Acid reflux
• Other atopic disease
• Occupation
• Days off?

Test
1) Acute asthma
• PEF
• Sputum culture
• FBC
• U&E
• CRP
• Blood culture
• ABG analysis
• CXR (to exclude infection/pneumothorax)

2) Chronic asthma
• PEF
• Diurnal variation
• Spirometry
• Skin-prick test
• Serology (aspergillosis)

Tx:
1) Chronic asthma
• Behavior – smoking, avoidance of precipitants, education
• BTSG:
Step 1: Ocassional short-acting inhaled B2-agonist (eg. Salbutamol) – next step if used >1 daily.
Step 2: standard-dose inhaled steroid (eg. Beclometasone 200ug/12h)
Step 3: long-acting B2-agonist (eg. Salmeterol) – if inadequate, increase dose of beclometasone 400ug/12h. if no effect of long-acting  stop
Step 4: trials of beclometasone 1000ug/12h,
modified-release of theophylline,
modified-release B2-agonist / oral leukotrine receptors
Step 5: prednisolone


DDx:
• Pulmonary oedema
• COPD
• Large airway obstruction
• SVC obstruction
• Pneumothorax
• PE
• Bronchiectasis
• Obliterative bronchiolitis

    About Me

    A medical student in Trinity College, University of Dublin, Ireland.

    Followers

    Labels